

EHA 2024 Congress

June 13–16, 2024
Madrid, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the EHA 2024 Congress, the Multiple Myeloma Hub Steering Committee has provided recommendations for the top abstracts to look out for in multiple myeloma.

EHA 2024: Top abstracts in MM

June 13–16, 2024

Top abstracts in multiple myeloma | Friday, June 14, 2024

Abstract	Title	Speaker	Time (CEST)
P911 View	TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B MONUMENTAL-2 STUDY	Emma Searle	18:00 (Poster Session)
P915 View	LONG-TERM EFFICACY AND SAFETY RESULTS FROM THE PHASE 1/2 MONUMENTAL-1 STUDY OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Leo Rasche	
P932 View	LONG-TERM SURVIVAL AFTER ELRANATAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAGNETISM-3	Mohamad Mohty	

Top abstracts in multiple myeloma | Saturday, June 15, 2024

Abstract	Title	Speaker	Time (CEST)
S201 View	DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF MINIMAL RESIDUAL DISEASE IN THE PERSEUS TRIAL	Pieter Sonneveld	11:45–12:00
S202 View	ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: POST TRANSPLANTATION INTERIM ANALYSIS OF THE RANDOMIZED PHASE III GMMG-HD7 TRIAL	Marc S. Raab	12:00–12:15
S100 View	PHASE 3 STUDY RESULTS OF ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) VERSUS VRD FOR TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (IMROZ)	Thierry Facon	14:45–15:00
S205 View	CILTACABTAGENE AUTOLEUCEL ± LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA WITH SUBOPTIMAL RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANT: CARTITUDE-2 COHORT D	Wilfried Roeloffzen	16:30–16:45
S208 View	IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS (PTS) WITH CLINICAL HIGH-RISK EARLY RELAPSE MULTIPLE MYELOMA (MM) WITHOUT FRONT-LINE (1L) AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): KARMMA-2 COHORT 2B	Xavier Leleu	17:15–17:30

Top abstracts in multiple myeloma | Sunday, June 16, 2024

Abstract	Title	Speaker	Time (CEST)
LB3440 View	RESULTS FROM THE RANDOMIZED PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS PMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN REPALPSED/REFRACTORY MULTIPLE MYELOMA	Meletios Dimopoulos	10:00 - 10:15
S210 View	CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY	Shaji Kumar	11:30 - 11:45
S212 View	LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE LINKER-MM1 STUDY: DEPTH AND DURABILITY OF RESPONSE AT 14-MONTH MEDIAN FOLLOW-UP	Suzanne Lentzsch	12:00–12:15
S214 View	RESULTS FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	María-Victoria Mateos	12:30–12:45



EHA 2024

Follow us on X to keep up to date
with the latest from the congress

@MM_Hub

#EHA2024

View all @MM_Hub tweets from #EHA2024



Brought to you by

